SCHEMBL13543

SCHEMBL13543

c1noc2c1CCCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15828432 0.98 SIGMAR1 (0.33)
SCHEMBL2589239 0.95
SCHEMBL10458506 0.74 CHRM5 (0.40)
SCHEMBL14123791 0.70
SCHEMBL20719781 0.70
SCHEMBL11069 0.70
SCHEMBL19642817 0.69 CYP2A6 (0.39)
SCHEMBL10882 0.69
SCHEMBL15828458 0.67 SIGMAR1 (0.33)
SCHEMBL15828457 0.67 FKBP5 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040254158-A1 Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US claimed
EP-1117661-B1 PROPANOLAMINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AVENTIS PHARMA GMBH (DE) 2004-05-26 EP claimed
EP-1117661-A1 PROPANOLAMINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF Aventis Pharma Deutschland GmbH (DE) 2001-07-25 EP claimed
WO-2000020410-A1 PROPANOLAMINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-04-13 WO claimed
JP-59015934-A None JP disclosed
EP-4688784-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 EP disclosed
US-20240343736-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-10-17 US disclosed
WO-2024206747-A1 KRAS INHIBITORS ELI LILLY AND COMPANY (US) 2024-10-03 WO disclosed
EP-4252755-A2 THERAPEUTIC COMPOUNDS C4x Discovery Limited (GB) 2023-10-04 EP disclosed
WO-2023179366-A1 OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 星希尔生物科技(上海)有限公司 2023-09-28 WO disclosed
EP-3870578-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2023-08-16 EP disclosed
US-20230159511-A1 TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS C4X DISCOVERY LIMITED (GB) 2023-05-25 US disclosed
US-6303639-B1 FOR THERAPY AND PROPHYLAXIS OF HYPERLIPIDEMIA, ARTERIOSCLEROTIC SYMPTOMS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-10-16 US disclosed
EP-1117661-A1 PROPANOLAMINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF Aventis Pharma Deutschland GmbH (DE) 2001-07-25 EP disclosed
EP-1035843-A2 I h?-MODULATORS Akzo Nobel N.V. (NL) 2000-09-20 EP disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
WO-2000020410-A1 PROPANOLAMINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-04-13 WO disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed
US-5256672-A Antipsychotic, analgesic HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-10-26 US disclosed
JP-S5915934-A COLORED PHOTOSENSITIVE SILVER HALIDE MATERIAL MITSUBISHI PAPER MILLS LTD 1984-01-27 JP disclosed